# Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

> **NCT03386344** · PHASE3 · TERMINATED · sponsor: **Lexicon Pharmaceuticals** · enrollment: 376 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Sotagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03386344
- **Lead sponsor:** Lexicon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-19
- **Primary completion:** 2019-05-22
- **Final completion:** 2020-05-30
- **Target enrollment:** 376 (ACTUAL)
- **Why stopped:** Study terminated prematurely for financial reasons and Covid-19 pandemic.
- **Last updated:** 2021-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03386344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03386344, "Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03386344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*